Novartis to Shut Down Sandoz Oral Solid Dosage Plant in North Carolina
Novartis said that it intends to shut down its Sandoz oral solid dosage plant in Wilson, N.C.
The news comes not long after Novartis announced that it is separating Sandoz, its generics and biosimilars division, and making it into a standalone company.
Novartis said the decision to shut down the North Carolina plant predated its decision to spin off Sandoz as an independent entity. The new publicly traded company will be Europe’s largest generics manufacturer.
Novartis plans on shutting down the Wilson, N.C. oral solid dosage plant by the end of 2023.